Brief: China Biotech Services Sees FY Net Loss Attributable Of HK$180 Million
03/03/2025 11:51
March 3 (Reuters) - China Biotech Services Holdings Ltd 8037.HK: SEES NET LOSS ATTRIBUTABLE OF HK$180 MILLION FOR FY2024 EXPECTED RESULT DUE TO REDUCTION IN REVENUE FROM DIMINISHED DEMAND FOR COVID-19 NUCLERIC ACID TEST, OTHERS Further company coverage: 8037.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on China Biotech Services Holdings
See all newsBrief: China Biotech Services Enters Cooperation Agreement
Brief: China Biotech Services Says HY Revenue From Cont Ops Hk$37.23 Million
Brief: China Biotech Services Expects HY Net Profit Of Not Less Than HK$15.0 MLN
Brief: China Biotech Services Enters Master Collaboration Agreement With Stella Pharma
Brief: China Biotech Services Says BGI Songhe Advances RMB30 Million Loan To Pengbo (Hainan)